



(THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES. THIS IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES.

THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.)



## Hannah Joseph Hospital (Institute of Neurosciences & Trauma)

(Please Scan this QR Code to view the Prospectus)

Registered Office: 134, Lake View Road K.K.Nagar, Madurai, Tamil Nadu, India, 625020. Corporate Office: Hannah Joseph Hospital RS 115-352, Madurai-Tuticorin Ring Road, Chintamani, Madurai, Madurai North, Tamil Nadu, India, 625009. Mob. No.: 9524729594; Contact Person: Yuvaraj Saravanan, Company Secretary &amp; Compliance Officer

E-mail id: cs@hannahjosephhospital.com; Website: <https://hannahjosephhospital.com/>; CIN: U74999TN2011PLC082860

PROMOTERS OF OUR COMPANY: Moses Joseph Arunkumar, Fenn Kavitha Fenn Arunkumar, Arunkumar Nalina and Noyel Arunkumar

OUR COMPANY HAS FILED THE PROSPECTUS DATED JANUARY 29, 2026, WITH THE ROC ON THURSDAY, JANUARY 29, 2026, AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF BSE LIMITED ("BSE SME" OR "STOCK EXCHANGE") AND THE TRADING IS EXPECTED TO COMMENCE ON MONDAY, FEBRUARY 02, 2026.

## BASIS OF ALLOTMENT

INITIAL PUBLIC ISSUE OF UP TO 60,00,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH ("EQUITY SHARES") OF HANNAH JOSEPH HOSPITAL LIMITED ("COMPANY" / "ISSUER") FOR CASH AT A PRICE OF ₹70/- PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹60/- PER EQUITY SHARE) ("ISSUE PRICE") AGGREGATING UP TO ₹4,200 LAKHS ("ISSUE"), OF WHICH 3,00,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH FOR CASH AT A PRICE OF ₹70/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹60/- PER EQUITY SHARE AGGREGATING TO ₹210 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION i.e. NET ISSUE OF 57,00,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH AT A PRICE OF ₹70/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹60/- PER EQUITY SHARE AGGREGATING ₹3,990 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 26.43% AND 25.11%, RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE FACE VALUE OF THE EQUITY SHARES IS ₹10/- EACH

ANCHOR INVESTOR ISSUE PRICE IS ₹70 PER EQUITY SHARE

THE ISSUE PRICE IS ₹70 PER EQUITY SHARE

THE ISSUE PRICE IS 7 TIMES OF THE FACE VALUE OF THE EQUITY SHARES

## RISKS TO INVESTORS

For details refer to section titled "Risk Factor" beginning on page 26 of the Prospectus.

## 1. Risk to Investors: Summary description of key risk factors based on materiality.

- We intend to utilize a portion of the Net Proceeds for setting up the Proposed Radiation Oncology Centre adjacent to the current hospital campus. We are yet to place orders for medical equipments and apply for requisite government approvals for the Proposed Radiation Oncology Centre. If we are unable to commission our Proposed Radiation Oncology Centre without time and cost overruns or unable to adhere to the schedule of implementation, it may adversely affect our business, results of operations and financial conditions.
- We are required to obtain statutory and regulatory approvals, licenses or permits for our proposed radiation oncology centre. If we fail to obtain, maintain or renew our statutory and regulatory approvals or permits, our business, results of operations, financial condition, and cash flows could be adversely affected.
- There are outstanding legal proceedings involving our Company. Any adverse decisions could impact our net worth, profitability, cashflows and divert management time and attention and have an adverse effect on our business, prospects, results of operations and financial condition.
- Our Company did not open a separate bank account for private placements made in the past, utilized the proceeds from the issuance prior filing of Form PAS-3, and issued private placement offer cum application letter before filing the Form MGT-14 with registrar and determined the relevant date within 30 days prior to the date of general meeting in violation of Section 42 of the Companies Act, 2013 and the rules made thereunder, which may have a material adverse effect on our business.
- While generating the UDIN for the Re-audited financial statements for FY 2023-24, the 'Certificate' category was selected due to unavailability of a specific 'Re-audit' or 'Restatement' option on the ICAI UDIN portal, which may be viewed as a procedural irregularity.

Details of suitable ratios of the Company for the latest full financial year ended March 31, 2025:

## 1. Basic and Diluted Earnings Per Share (EPS):

Sr. No.	Financial Year/Period	Basic & Diluted EPS (in ₹)	Weights	EPS x Weight
1	Financial Year ended March 31, 2025	4.32	3	12.96
2	Financial Year ended March 31, 2024	2.47	2	4.94
3	Financial Year ended March 31, 2023	0.63	1	0.63
	<b>Weighted Average</b>			<b>3.09</b>
	<b>Total</b>			<b>6</b>
	<b>Period ended September 30, 2025*</b>			<b>3.07</b>

\*Not Annualized

Notes:

1. The figures disclosed above are based on the Restated Financial Statements of the Company.

2. The face value of each Equity Share is ₹ 10.00.

3. Weighted average = Aggregate of year-wise weighted EPS divided by the aggregate of weights i.e. sum of (EPS x Weight) for each year/Total of weights.

4. Earnings per Share has been calculated in accordance with Indian Accounting Standard 33 – "Earnings per Share".

## 2. Price to Earnings (P/E) ratio in relation to Price Band of ₹67 and ₹70 per Equity Shares

Particulars	EPS (in ₹)	P/E Ratio at the Floor Price (No. of times)	P/E Ratio at the Cap Price (No. of times)
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2024-25	4.32	15.51	16.20
P/E ratio based on the Weighted Average EPS, as restated	3.09	21.68	22.65

## BID / ISSUE PROGRAMME

ANCHOR INVESTOR BIDDING DATE OPENED AND CLOSED ON: WEDNESDAY, JANUARY 21, 2026

BID / ISSUE OPENED ON: THURSDAY, JANUARY 22, 2026 | BID / ISSUE CLOSED ON WEDNESDAY, JANUARY 28, 2026

PROPOSED LISTING: MONDAY, FEBRUARY 02, 2026\*

\*Subject to the receipt of listing and trading approval from the BSE.

The issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), out of which 33.33% of the Anchor Investor Portion shall be reserved for domestic Mutual Funds and 6.67% for life insurance companies and pension funds, subject to valid bids being received from domestic Mutual Funds, life insurance companies and pension funds at or above the Anchor Investor Allocation Price, in accordance with the SEBI ICDR Regulations. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders of which (a) one-third of portion shall be reserved for applicants with application size of more than two lots and up to ₹10,00,000, and (b) two-third of such portion shall be reserved for applicants with application size of more than ₹10,00,000, provided that the unsubscribed portion in either of such sub-categories may be allocated to applicants in the other sub-category of Non-Institutional Bidders, in accordance with the SEBI ICDR Regulations, subject to valid bids being received at or above the Issue Price and not less than 35% of the Net Issue shall be available for allocation to Individual Bidders who applies for minimum application size in accordance with the SEBI ICDR Regulations, subject to valid bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective bank accounts (including UPI ID for UPI Bidder using the UPI Mechanism) (defined hereinafter), in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks ("SCSBs") or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the issue through the ASBA process. For details, see "Issue Procedure" beginning on page no. 256 of the Prospectus.

## SUBSCRIPTION DETAILS

The bidding for Anchor Investors opened and closed on January 21, 2026. The Company received 7 Anchor Investors applications for 2290500 Equity Shares against 1706000 Equity Shares reserved for Anchor Investors. The Anchor Investor Allocation price was finalized at ₹70 per Equity Share. A total of 1706000 Equity Shares were allotted under the Anchor Investor portion aggregating to ₹19420000/-.

The issue (including Anchor Investors Portion) received 887 Applications for 8666500 Equity Shares (prior to rejections) resulting in 1.35 times subscription (including reserved portion of market maker). The details of the Applications received in the issue from various categories are as under:

Detail of the Applications Received from various categories including market maker are as under:

Sr. No.	Category	No. of Applications received	No. of Equity Shares applied	No. of Equity Shares reserved as per Prospectus	No. of times Subscribed	Amount (₹)
1	Qualified Institutional Bidders (excluding Anchor Investors)	5	1230000	1140000	1.08	8610000
2	Non-Institutional Investors - More than 2 Lakhs Upto 10 Lakhs	53	370000	286000	1.29	2590000
3	Non-Institutional Investors - Above 10 Lakhs	35	1332000	572000	2.33	9324000
4	Individual Investors	786	3144000	1996000	1.58	22008000
5	Anchor Investors	7	2290500	1706000	1.34	16033500
6	Market Maker	1	300000	300000	1.00	2100000
<b>Total</b>		<b>887</b>	<b>8666500</b>	<b>6000000</b>	<b>1.35</b>	<b>606655000</b>

Final Demand:

A summary of final demand (prior to any rejections) as per BSE as on the Bid/Issue Closing Date at different prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Share Total	Cumulative % of Total
1	67.00	296000	1.63	296000	1.63
2	68.00	142000	0.78	438000	2.41
3	69.00	56000	0.31	494000	2.72
4	70.00	1766000	97.28	18154000	100.00
<b>Total</b>		<b>18154000</b>			

The basis of allotment was finalized in consultation with the Designated Stock Exchange, being BSE Limited (BSE SME) on January 29, 2026.

## a) Allotment to Individual Investors (After Rejections &amp; Withdrawal):

The Basis of Allotment to the Individual Investors, who have Bid at cut-off Price or at or above the Issue Price of ₹70/- per Equity Share, was finalized in consultation with BSE SME.

The category was subscribed by 1.58 times i.e., for 3144000 Equity Shares. The total number of Equity Shares allotted in this category is 1996000 Equity Shares to 499 successful applicants.

The category wise details of the Basis of Allotment are as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each	% to total	Allocation per Applicant	Ratio of allottees to applicants	Number of successful applicants (after rounding)	% to total	Total No. of shares allocated/ allotted	% to total	Surplus/ Deficit (14)-(7)
1	4000	786	100	3144000	100	2539.44	4000	499	786	499	100	0

Grand Total

53 100 370000 100 499 100 100 0

## b) Allotment to Non-Institutional Investors (More than Rs. 2 lakhs Up to Rs. 10 lakhs) (After Technical Rejections &amp; Withdrawal):





## Hannah Joseph Hospital

(Institute of Neurosciences & Trauma)

(THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES. THIS IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.)

# Hannah Joseph Hospital Limited

(formerly Hannah Joseph Hospital Private Limited)

Our Company was incorporated as "Hannah Joseph Hospital Private Limited" at Tamil Nadu as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated October 24, 2011, issued by the Registrar of Companies ("ROC"), Tamil Nadu, Chennai, Andaman and Nicobar Islands. Subsequently, our Company was converted to a public limited company and the name of our Company changed to "Hannah Joseph Hospital Limited" and a fresh certificate of incorporation dated July 29, 2022 was issued by the ROC, Chennai. The CIN of our Company is U74999TN2011PLC082860. For details in relation to changes in the registered office of our Company, see "History and Corporate Structure" on page no. 152 of the Prospectus.

Registered Office: 134, Lake View Road K.K.Nagar, Madurai, Tamil Nadu, India, 625020. Corporate Office: Hannah Joseph Hospital RS 115-382, Madurai-Tuticorin Ring Road, Chintamani, Madurai, Madurai North, Tamil Nadu, India, 625009. Mob. No.: 9524729594; Contact Person: Yuvaraj Saravanan, Company Secretary & Compliance Officer. E-mail id: cs@hannahjosephhospital.com; Website: <https://hannahjosephhospital.com/>; CIN: U74999TN2011PLC082860

**PROMOTERS OF OUR COMPANY: Moses Joseph Arunkumar, Fenn Kavitha Fenn Arunkumar, Arunkumar Nalina and Noyel Arunkumar**

OUR COMPANY HAS FILED THE PROSPECTUS DATED JANUARY 29, 2026, WITH THE ROC ON THURSDAY, JANUARY 29, 2026, AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF BSE LIMITED ("BSE SME" OR "STOCK EXCHANGE") AND THE TRADING IS EXPECTED TO COMMENCE ON MONDAY, FEBRUARY 02, 2026.

### BASIS OF ALLOTMENT

INITIAL PUBLIC ISSUE OF UP TO 60,00,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH ("EQUITY SHARES") OF HANNAH JOSEPH HOSPITAL LIMITED ("COMPANY" / "ISSUER") FOR CASH AT A PRICE OF ₹70/- PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹60/- PER EQUITY SHARE) ("ISSUE PRICE") AGGREGATING UP TO ₹4,200 LAKHS ("ISSUE"), OF WHICH 3,00,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH FOR CASH AT A PRICE OF ₹70/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹60/- PER EQUITY SHARE AGGREGATING TO ₹210 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION i.e. NET ISSUE OF 57,00,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH AT A PRICE OF ₹70/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹60/- PER EQUITY SHARE AGGREGATING ₹3,990 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 26.43% AND 25.11%, RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

**THE FACE VALUE OF THE EQUITY SHARES IS ₹10/- EACH**

**ANCHOR INVESTOR ISSUE PRICE IS ₹70 PER EQUITY SHARE**

**THE ISSUE PRICE IS ₹70 PER EQUITY SHARE**

**THE ISSUE PRICE IS 7 TIMES OF THE FACE VALUE OF THE EQUITY SHARES**

### RISKS TO INVESTORS

For details refer to section titled "Risk Factor" beginning on page 26 of the Prospectus.

**1. Risk to Investors: Summary description of key risk factors based on materiality.**

- We intend to utilize a portion of the Net Proceeds for setting up the Proposed Radiation Oncology Centre adjacent to the current hospital campus. We are yet to place orders for medical equipments and apply for requisite government approvals for the Proposed Radiation Oncology Centre. If we are unable to commission our Proposed Radiation Oncology Centre without time and cost overruns or unable to adhere to the schedule of implementation, it may adversely affect our business, results of operations and financial conditions.
- We are required to obtain statutory and regulatory approvals, licenses or permits for our proposed radiation oncology centre. If we fail to obtain, maintain or renew our statutory and regulatory approvals or permits, our business, results of operations, financial condition, and cash flows could be adversely affected.
- There are outstanding legal proceedings involving our Company. Any adverse decisions could impact our net worth, profitability, cashflows and divert management time and attention and have an adverse effect on our business, prospects, results of operations and financial condition.
- Our Company did not open a separate bank account for private placements made in the past, utilized the proceeds from the issuance prior filing of Form PAS-3, and issued private placement offer cum application letter before filing the Form MGT-14 with registrar and determined the relevant date within 30 days prior to the date of general meeting in violation of Section 42 of the Companies Act, 2013 and the rules made thereunder, which may have a material adverse effect on our business.
- While generating the UDIN for the Re-audited financial statements for FY 2023-24, the 'Certificate' category was selected due to unavailability of a specific 'Re-audit' or 'Restatement' option on the ICAI UDIN portal, which may be viewed as a procedural irregularity.

Details of suitable ratios of the Company for the latest full financial year ended March 31, 2025:

**1. Basic and Diluted Earnings Per Share (EPS):**

Sr. No.	Financial Year/Period	Basic & Diluted EPS (in ₹)	Weights	EPS x Weight
1	Financial Year ended March 31, 2025	4.32	3	12.96
2	Financial Year ended March 31, 2024	2.47	2	4.94
3	Financial Year ended March 31, 2023	0.63	1	0.63
	<b>Weighted Average</b>			<b>3.09</b>
	<b>Total</b>			<b>6</b>
	<b>Period ended September 30, 2025*</b>			<b>3.07</b>

\*Not Annualized

Notes:

1. The figures disclosed above are based on the Restated Financial Statements of the Company.

2. The face value of each Equity Share is ₹ 10.00.

3. Weighted average = Aggregate of year-wise weighted EPS divided by the aggregate of weights i.e. sum of (EPS x Weight) for each year/Total of weights.

4. Earnings per Share has been calculated in accordance with Indian Accounting Standard 33 – "Earnings per Share".

**2. Price to Earnings (P/E) ratio in relation to Price Band of ₹67 and ₹70 per Equity Shares**

Particulars	EPS (in ₹)	P/E Ratio at the Floor Price (No. of times)	P/E Ratio at the Cap Price (No. of times)
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2024-25	4.32	15.51	16.20
P/E ratio based on the Weighted Average EPS, as restated	3.09	21.68	22.65

### BID / ISSUE PROGRAMME

**ANCHOR INVESTOR BIDDING DATE OPENED AND CLOSED ON: WEDNESDAY, JANUARY 21, 2026**

**BID / ISSUE OPENED ON: THURSDAY, JANUARY 22, 2026 | BID / ISSUE CLOSED ON WEDNESDAY, JANUARY 28, 2026**

**PROPOSED LISTING: MONDAY, FEBRUARY 02, 2026\***

\*Subject to the receipt of listing and trading approval from the BSE.

The issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(ii) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), out of which 33.33% of the Anchor Investor Portion shall be reserved for domestic Mutual Funds and 6.67% for life insurance companies and pension funds, subject to valid bids being received from domestic Mutual Funds, life insurance companies and pension funds at or above the Anchor Investor Allocation Price, in accordance with the SEBI ICDR Regulations. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders of which (a) one-third of portion shall be reserved for applicants with application size of more than two lots and up to ₹10,00,000, and (b) two-third of such portion shall be reserved for applicants with application size of more than ₹10,00,000, provided that the unsubscribed portion in either of such sub-categories may be allocated to applicants in the other sub-category of Non-Institutional Bidders, in accordance with the SEBI ICDR Regulations, subject to valid bids being received at or above the Issue Price and not less than 35% of the Net Issue shall be available for allocation to Individual Bidders who applies for minimum application size in accordance with the SEBI ICDR Regulations, subject to valid bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective bank accounts (including UPI ID for UPI Bidder using the UPI Mechanism) (defined hereinafter), in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks ("SCSBs") or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the issue through the ASBA process. For details, see "Issue Procedure" beginning on page no. 256 of the Prospectus.

### SUBSCRIPTION DETAILS

The bidding for Anchor Investors opened and closed on January 21, 2026. The Company received 7 Anchor Investors applications for 2290500 Equity Shares against 1706000 Equity Shares reserved for Anchor Investors. The Anchor Investor Allocation price was finalized at ₹70 per Equity Share. A total of 1706000 Equity Shares were allotted under the Anchor Investor portion aggregating to ₹19420000/-.

The issue (including Anchor Investors Portion) received 887 Applications for 8666500 Equity Shares (prior to rejections) resulting in 1.35 times subscription (including reserved portion of market maker). The details of the Applications received in the issue from various categories are as under:

Detail of the Applications Received from various categories including market maker are as under:

Sr. No.	Category	No. of Applications received	No. of Equity Shares applied	No. of Equity Shares reserved as per Prospectus	No. of times Subscribed	Amount (₹)
1	Qualified Institutional Bidders (excluding Anchor Investors)	5	1230000	1140000	1.08	8610000
2	Non-Institutional Investors - More than 2 Lakhs Upto 10 Lakhs	53	370000	286000	1.29	2590000
3	Non-Institutional Investors - Above 10 Lakhs	35	1332000	572000	2.33	9324000
4	Individual Investors	786	3144000	1996000	1.58	22008000
5	Anchor Investors	7	2290500	1706000	1.34	16033500
6	Market Maker	1	300000	300000	1.00	2100000
<b>Total</b>		<b>887</b>	<b>8666500</b>	<b>6000000</b>	<b>1.35</b>	<b>606655000</b>

Final Demand:

A summary of final demand (prior to any rejections) as per BSE as on the Bid/Issue Closing Date at different prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Share Total	Cumulative % of Total
1	67.00	296000	1.63	296000	1.63
2	68.00	142000	0.78	438000	2.41
3	69.00	56000	0.31	494000	2.72
4	70.00	1766000	97.28	18154000	100.00
<b>Total</b>		<b>18154000</b>			

The basis of allotment was finalized in consultation with the Designated Stock Exchange, being BSE Limited (BSE SME) on January 29, 2026.

**a) Allotment to Individual Investors (After Rejections & Withdrawal):**

The Basis of Allotment to the Individual Investors, who have Bid at cut-off Price or at or above the Issue Price of ₹70/- per Equity Share, was finalized in consultation with BSE SME. The category was subscribed by 1.58 times i.e., for 3144000 Equity Shares. The total number of Equity Shares allotted in this category is 1996000 Equity Shares to 499 successful applicants.

The category wise details of the Basis of Allotment are as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each	% to total	Allocation per Applicant	Ratio of allottees to applicants	Number of successful applicants (after rounding)	% to total	Total No. of shares allocated/ allotted	% to total
---------	---	---------------------------------	------------	-------------------------------------	------------	--------------------------	----------------------------------	--	------------	---	------------

## APP-BASED ENUMERATION WIDENS RISK SURFACE

## Digital route for Census raises cyber risk worries

Exercise will cover more than 1.4 billion people

URVI MALVANIA  
Mumbai, January 30

AS THE GOVERNMENT prepares for the next population census, cybersecurity is emerging as a central operational concern, with experts maintaining that as much as a quarter of the total budget may need to be allocated to securing digital systems.

The shift to app-based data collection for the first time, replacing paper schedules with mobile and web platforms, has significantly expanded the risk surface, exposing the exercise to threats ranging from data leaks to system disruption.

The scale of the exercise — covering more than 1.4 billion people — means cybersecurity is no longer a back-end technology issue but a core governance challenge. With millions of enumerators using hand-held devices and temporary logins, the census will involve one of the largest real-time data collection exercises undertaken anywhere in the world.

"Key measures include end-to-end encryption, multi-layered security protocols for mobile applications and web portals, and stringent access controls. For such a critical initiative, around 25–30% of the overall budget should be earmarked for cybersecurity," Chetan Jain, founder and managing director at Inspira Enterprises, told *FE*.

Unlike earlier censuses, where physical forms limited exposure, the digital format requires protection across the entire data lifecycle — from the moment information is captured in the field to its storage, processing and eventual use. Any breach or prolonged disruption could undermine the integrity of official statistics and erode public trust in one of the country's most important administrative exercises. Secu-



## RISK ASSESSMENT

■ Experts say around 25–30% of overall budget should be earmarked for cybersecurity

■ Mobiles, web platforms will replace paper schedules

■ Exercise exposed to threats ranging from data leak to system disruption

Census will involve one of largest real-time data collection exercises in the world

■ Digital format of data collection requires protection across entire data lifecycle

■ Any breach or disruption in data could undermine integrity of official statistics and erode public trust, warn experts

■ Enumerators will rely on smartphones, tablets, hand-held devices, making endpoint security critical

THE US WILL return three ancient bronze sculptures to India that were illegally removed from the country's temples.

The Smithsonian's National Museum of Asian Art in Washington DC said that three sculptures will be returned to the Government of India, following "rigorous provenance research" that documented the sculptures had been removed illegally from temple settings.

A statement issued by the museum said that the Indian government has agreed to place one of the sculptures on long-term loan, an arrangement that will allow the museum to publicly share the full story of the object's origins, removal and return, and to underscore the museum's commitment to provenance research.

The sculptures are 'Shiva Nataraja' belonging to the Chola period, circa 990; 'Somaskanda' of the Chola period, 12th century; and 'Saint Sundarar with Paravai' of the Vijayanagar period, 16th century.

PTI

The incident occurred in the afternoon at the office-cum-bungalow, with a senior police officer saying Roy allegedly used a pistol he had in his possession.

He was rushed to a private hospital and then to Narayana Hospital, where he was declared dead on arrival.

Running one of Kerala's leading real estate firms that spanned India and beyond, Roy is known for making projects without availing bank loans — or a zero-debt business, as he called it.

"We are proud to say that none of our gigantic portfolio of 159 projects has been stalled due to any reasons — from the organisation or prop-



Confident Group chairman C.J. Roy is known for making projects without availing bank loans — or a zero-debt business, as he called it

glomerate with multiple business activities spread across India, the UAE and the US.

"We also have the pride of designing and delivering multiple well-appreciated real estate projects and products across Bangalore, Kerala and Dubai."

"We are a 19-year-old con-

erty titles or governmental issues," the message reads.

"We have also achieved CRISIL 7 Star rating for a few of our projects."

"Real estate products are based on trust and faith, and all our projects come with the best of land titles vetted by multiple advocates and also pass the stringent legal scrutiny of multiple banks," it states.

According to the Kerala Real Estate Regulatory Authority, the company had 20 projects in progress at various locations in the state, including Thiruvananthapuram, Kochi, Kozhikode, Malappuram and Thrissur.

Roy has also produced several films, salvaging projects that were facing a crisis, and sponsored TV shows.

His first production was *Casanova*, a big-budget film from 2012. In 2021, he was part of the production of *Mohanal*-starrer *Marakkar: Lion of the Arabian Sea*.

Last year, he produced *Tovino* Thomas-starrer *Identity*.

He was also known as much for his luxury cars as he was for his social welfare activities.

## Sunetra Pawar set to be deputy CM of Maha; NCP merger talks on backburner

PRESS TRUST OF INDIA  
Mumbai/Pune, January 30

RAJYA SABHA MP Sunetra Pawar is likely to be sworn-in as Maharashtra Deputy Chief Minister on Saturday, replacing her late husband Ajit Pawar in the cabinet, said NCP sources on Friday, signalling the party's continuation in ruling Mahayuti and delaying merger talks.

She would be the first woman to hold the post of deputy chief minister in the state, where the position was first created in 1978 when the coalition government era began in Maharashtra.

Following the death of Deputy Chief Minister Ajit Pawar in an air crash in Bara-



Devendra Fadnavis-led cabinet.

Her consent to accept the decision to name her as her husband's successor has been communicated to party leaders, said the sources.

"Tomorrow (Saturday), a parliamentary board meeting of the party will take place in Mumbai, where Sunetra Pawar will be elected as the leader of the NCP legislature party," said a source.

"It is likely that she will be sworn-in as Deputy Chief Minister by tomorrow evening," said the source privy to the developments.

Speaking to reporters in Nagpur, Chief Minister Devendra Fadnavis said the BJP, which heads the ruling alliance

Mahayuti, would support any decision taken by the family and party of late Ajit Pawar.

"The NCP will take whatever decision it has to take for the post of deputy chief minister, and the government and the BJP will support the decision. I can only tell you that we are standing behind the family of Ajit Dada and the NCP," the CM added.

Until the 2024 Lok Sabha elections, Sunetra Pawar had kept a low profile.

In the general elections that year, she stood from Baranati as the candidate of her husband's party, but was defeated by her sister-in-law and incumbent NCP (SP) MP Supriya Sule in the prestige battle.

**Krystal Integrated Services Limited**  
(Formerly known as Krystal Integrated Services Private Limited)  
Registered Office Address: Krystal House, 15A 17, Shivaji Fort CHS, Duncans Causeway Road, Mumbai - 400 022, Maharashtra, India  
Tel: 022-4747 1234, 022-4353 1234  
Website: [www.krystal-group.com](http://www.krystal-group.com) Email: [company.secretary@krystal-group.com](mailto:company.secretary@krystal-group.com)  
CIN: L74920MH2000PLC129827

**POSTAL BALLOT NOTICE AND E-VOTING INFORMATION**  
Notice is hereby given that Krystal Integrated Services Limited ("the Company"), pursuant to the provisions of Section 108, 110 and other applicable provisions, if any, of the Companies Act, 2013 ("the Act"), read with Rules 20 and 22 of the Companies (Management and Administration) Rules, 2014 ("the Rules"), Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations), (including any statutory modification(s) or re-enactment(s) thereof for the time being in force) read with the General Circular No. 14/2020 dated April 8, 2020, General Circular No. 17/2020 dated April 13, 2020, and various subsequent circulars issued, read with General Circular No. 09/2024 dated September 19, 2024 and General Circular No. 03/2025 dated September 22, 2025 issued by the Ministry of Corporate Affairs (hereinafter collectively referred to as "MCA Circulars"), and the Secretarial Standard on General Meetings issued by the Institute of Company Secretaries of India (SS-2) and other applicable laws, rules and regulations, if any, is seeking approval of the Members of the Company, by way of Postal Ballot, only through remote e-voting process, in relation to the following Ordinary and Special Resolutions as set out in the Postal Ballot Notice ("Notice") dated January 22, 2026:

- a. Increase in Authorised Share Capital of the Company and consequential amendment to the Memorandum of Association of the Company; and

- b. Approval to raise capital by way of a Qualified Institutions Placement to eligible investors through an issuance of Equity Shares for an amount aggregating up to Rs. 300 Crores (Rupees Three Hundred Crores only) in one or more tranches.

The Company has completed dispatch of the Notice on Friday, January 30, 2026 through electronic mode, to those Members whose names are recorded in the Register of Members / List of Beneficial Owners as received from National Securities Depository Limited ("NSDL") and Central Depository Services (India) Limited ("CDSL") as on Friday, January 23, 2026 ("cut-off date" and who have registered their e-mail addresses with the Company / Company's Registrar to an Issue and Share Transfer Agent i.e. MUFG Intime India Private Limited (Formerly Link Infime India Private Limited) ("MUFG") / Depository Participants ("DPs"). Accordingly, physical copy of the Notice, postal ballot form and pre-paid business reply envelope have not been sent to Members for this Postal Ballot.

The Notice is available on the Company's website at [www.krystal-group.com](http://www.krystal-group.com) in the investors section, on the websites of the Stock Exchanges i.e. BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) respectively, and on the website of NSDL at [www.evoting.nsdl.com](http://www.evoting.nsdl.com).

Members whose names appear in the Register of Members / List of Beneficial Owners as on the cut-off date shall be entitled to vote in relation to the resolutions specified in the Notice.

The voting rights of the Members shall be in proportion to their shares in the total paid-up equity share capital of the Company, as on the cut-off date. A person who is not a member as on the cut-off date should treat this Notice for information purpose only.

The Company has engaged the services of NSDL to provide remote e-voting facility to its Members.

The remote e-voting period commences on Saturday, January 31, 2026 from 9:00 a.m. (IST) and ends on Sunday, March 01, 2026 at 5:00 p.m. (IST). The remote e-voting module shall be disabled by NSDL for voting thereafter.

Once the vote on a resolution is cast by a member, the same will not be allowed to change subsequently. The Members holding shares in electronic form and who have not updated their email address of KYC details are requested to register/update the details in their demat account as per the process advised by respective DPs.

Ms. Kajal Jakharia of M/s. Kajal Jakharia & Associates, a peer reviewed firm of Practicing Company Secretaries (Membership No. FCS 7922 / C.P. No. 23149), has been appointed as the Scrutinizer, to conduct the postal ballot through remote e-voting process in a fair and transparent manner.

The result of the voting conducted by Postal Ballot shall be declared not later than two working days from the conclusion of the remote e-voting. The said results along with the Scrutinizer's Report shall be placed on the Company's website at [www.krystal-group.com](http://www.krystal-group.com) and on the website of NSDL at [www.evoting.nsdl.com](http://www.evoting.nsdl.com) and simultaneously be communicated to BSE and NSE, where the equity shares of the Company are listed.

In case of any queries, Members may write to the Company at [company.secretary@krystal-group.com](mailto:company.secretary@krystal-group.com). Further for any queries pertaining to e-voting, Members are requested to refer the Frequently Asked Questions (FAQs) for shareholders and e-voting user manual for shareholders available at the download section of [www.evoting.nsdl.com](http://www.evoting.nsdl.com) or call on toll free no.: 022- 4886 7000 or send a request to Mr. Abhijeet Gujral, Deputy Manager, NSDL at [evoting@nsdl.co.in](mailto:evoting@nsdl.co.in).

For Krystal Integrated Services Limited  
(Formerly known as Krystal Integrated Services Private Limited)  
Sd/-  
Manishkumar Sangani  
Company Secretary & Compliance Officer  
Membership No.:A24671

Place: Mumbai  
Date: January 30, 2026

(THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES. THIS IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.)



(Please scan this QR Code to view the Offer Document)



Hannah Joseph Hospital  
(Institute of Neurosciences & Trauma)

## Hannah Joseph Hospital Limited

(formerly Hannah Joseph Hospital Private Limited)

Our Company was incorporated as "Hannah Joseph Hospital Private Limited" at Tamil Nadu as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated October 24, 2011, issued by the Registrar of Companies ("ROC"), Tamil Nadu, Chennai, Andaman and Nicobar Islands. Subsequently, our Company was converted to a public limited company and the name of our Company changed to "Hannah Joseph Hospital Limited" and a fresh certificate of incorporation dated July 29, 2022 was issued by the RoC, Chennai. The CIN of our Company is U74999TN2011PLC062860. For details in relation to changes in the registered office of our Company, see "History and Corporate Structure" on page no. 152 of the Red Herring Prospectus.

PROMOTERS OF OUR COMPANY: Mosesjoseph Arunkumar, Fenn Kavitha Fenn Arunkumar, Arunkumar Nalina and Noyel Arunkumar

PRICE BAND: ₹ 67 TO ₹ 70 PER EQUITY SHARE OF FACE VALUE ₹ 10/- EACH

## ALLOCATION OF THE OFFER

QIB PORTION NOT MORE THAN 50% OF THE NET ISSUE • INDIVIDUAL INVESTOR PORTION NOT LESS THAN 35% OF THE NET ISSUE

NON-INSTITUTIONAL PORTION NOT LESS THAN 15% OF THE NET ISSUE • MARKET MAKER PORTION NOT LESS THAN 5% OF THE NET ISSUE

THE FLOOR PRICE IS 6.7 TIMES OF THE FACE VALUE OF THE EQUITY SHARES AND THE CAP PRICE IS 7 TIMES OF THE FACE VALUE OF THE EQUITY SHARES  
THE PRICE TO EARNING RATIO BASED ON RESTATED DILUTED EPS FOR FISCAL 2025 AT THE FLOOR PRICE IS 15.51 TIMES AND AT THE CAP PRICE IS 16.2 TIMES.

BIDS CAN BE MADE FOR A MINIMUM OF 4000 EQUITY SHARES AND IN MULTIPLES OF 2000 EQUITY SHARES THEREAFTER.

IN MAKING AN INVESTMENT DECISION, POTENTIAL INVESTORS MUST ONLY RELY ON THE INFORMATION INCLUDED IN THE RED HERRING PROSPECTUS AND THE TERMS OF THE ISSUE, INCLUDING THE RISKS INVOLVED AND NOT RELY ON ANY OTHER EXTERNAL SOURCES OF INFORMATION ABOUT THE ISSUE AVAILABLE IN ANY MANNER.

## CORRIGENDUM

This is with reference to the Corrigendum to the Issue open extended advertisement published on January 28, 2026 and prospectus dated January 29, 2026.

## Indicative timeline for the issue

Bid/ Issue Program: Commencement of trading of the equity shares on the stock exchange On or about Monday, February 02, 2026.

GENERAL RISK: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the issue. For taking an investment decision, investors must rely on their own examination of our Company and the issue including the risks involved. The Equity Shares issued in the issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the Red Herring Prospectus. Specific attention of the investors is invited to the section "Risk Factors" on page no. 26 of the Red Herring Prospectus.

BOOK RUNNING LEAD MANAGER TO THE ISSUE CAPITALSQUARE® Teamimg together to create value

REGISTRAR TO THE ISSUE BIGSHARE SERVICES PRIVATE LIMITED



Bigshare Services Private Limited

Address: Office no S6-2, 6th Floor, Pinnacle Business Park,


Next to Ahura Centre, Mahakali Caves Road, Andheri (East),

Mumbai – 400093, Maharashtra, India

Contact No: +91 – 22 – 6263 8200, Email: [ipo@bigshareonline.com](mailto:ipo@bigshareonline.com)

Website: [www.bigshareonline.com](http://www.bigshareonline.com)

(THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES. THIS IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES.  
THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.)



**Hannah Joseph Hospital**  
(Institute of Neurosciences & Trauma)

(Please Scan this QR Code to view the Prospectus)

# Hannah Joseph Hospital Limited

(formerly Hannah Joseph Hospital Private Limited)

Our Company was incorporated as "Hannah Joseph Hospital Private Limited" at Tamil Nadu as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated October 24, 2011, issued by the Registrar of Companies ("ROC"), Tamil Nadu, Chennai, Andaman and Nicobar Islands. Subsequently, our Company was converted to a public limited company and the name of our Company changed to "Hannah Joseph Hospital Limited" and a fresh certificate of incorporation dated July 29, 2022 was issued by the ROC, Chennai. The CIN of our Company is U74999TN2011PLC082860. For details in relation to changes in the registered office of our Company, see "History and Corporate Structure" on page no. 152 of the Prospectus.

Registered Office: 134, Lake View Road K.K.Nagar, Madurai, Tamil Nadu, India, 625020. Corporate Office: Hannah Joseph Hospital RS 115-3B2, Madurai-Tuticorin Ring Road, Chintamani, Madurai, Madurai North, Tamil Nadu, India, 625009. Mob. No.: 9524729594; Contact Person: Yuvraj Saravanan, Company Secretary & Compliance Officer E-mail id: cs@hannahjosephhospital.com; Website: https://hannahjosephhospital.com/; CIN: U74999TN2011PLC082860

**PROMOTERS OF OUR COMPANY: Mosesjoseph Arunkumar, Fenn Kavitha Fenn Arunkumar, Arunkumar Nalina and Noyel Arunkumar**

OUR COMPANY HAS FILED THE PROSPECTUS DATED JANUARY 29, 2026, WITH THE ROC ON THURSDAY, JANUARY 29, 2026, AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF BSE LIMITED ("BSE SME" OR "STOCK EXCHANGE") AND THE TRADING IS EXPECTED TO COMMENCE ON MONDAY, FEBRUARY 02, 2026.

## BASIS OF ALLOTMENT

INITIAL PUBLIC ISSUE OF UP TO 60,00,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH ("EQUITY SHARES") OF HANNAH JOSEPH HOSPITAL LIMITED ("COMPANY" / "ISSUER") FOR CASH AT A PRICE OF ₹70/- PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹60/- PER EQUITY SHARE) ("ISSUE PRICE") AGGREGATING UP TO ₹4,200 LAKHS ("ISSUE"), OF WHICH 3,00,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH FOR CASH AT A PRICE OF ₹70/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹60/- PER EQUITY SHARE AGGREGATING TO ₹210 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION i.e. NET ISSUE OF 57,00,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH AT A PRICE OF ₹70/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹60/- PER EQUITY SHARE AGGREGATING TO ₹3,990 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 26.43% AND 25.11%, RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

**THE FACE VALUE OF THE EQUITY SHARES IS ₹10/- EACH**

**ANCHOR INVESTOR ISSUE PRICE IS ₹70 PER EQUITY SHARE**

**THE ISSUE PRICE IS ₹70 PER EQUITY SHARE**

**THE ISSUE PRICE IS 7 TIMES OF THE FACE VALUE OF THE EQUITY SHARES**

## RISKS TO INVESTORS

For details refer to section titled "Risk Factor" beginning on page 26 of the Prospectus.

**1. Risk to Investors: Summary description of key risk factors based on materiality.**

1. We intend to utilize a portion of the Net Proceeds for setting up the Proposed Radiation Oncology Centre adjacent to the current hospital campus. We are yet to place orders for medical equipments and apply for requisite government approvals for the Proposed Radiation Oncology Centre. If we are unable to commission our Proposed Radiation Oncology Centre without time and cost overruns or unable to adhere to the schedule of implementation, it may adversely affect our business, results of operations and financial conditions.
2. We are required to obtain statutory and regulatory approvals, licenses or permits for our proposed radiation oncology centre. If we fail to obtain, maintain or renew our statutory and regulatory approvals or permits, our business, results of operations, financial condition, and cash flows could be adversely affected.
3. There are outstanding legal proceedings involving our Company. Any adverse decisions could impact our net worth, profitability, cashflows and divert management time and attention and have an adverse effect on our business, prospects, results of operations and financial condition.
4. Our Company did not open a separate bank account for private placements made in the past, utilized the proceeds from the issuance prior filing of Form PAS-3, and issued private placement offer cum application letter before filing the Form MGT-14 with registrar and determined the relevant date within 30 days prior to the date of general meeting in violation of Section 42 of the Companies Act, 2013 and the rules made thereunder, which may have a material adverse effect on our business.
5. While generating the UDIN for the Re-audited financial statements for FY 2023-24, the 'Certificate' category was selected due to unavailability of a specific 'Re-audit' or 'Restatement' option on the ICAI UDIN portal, which may be viewed as a procedural irregularity.

Details of suitable ratios of the Company for the latest full financial year ended March 31, 2025:

**1. Basic and Diluted Earnings Per Share (EPS):**

Sr. No.	Financial Year/Period	Basic & Diluted EPS (in ₹)	Weights	EPS x Weight
1	Financial Year ended March 31, 2025	4.32	3	12.96
2	Financial Year ended March 31, 2024	2.47	2	4.94
3	Financial Year ended March 31, 2023	0.63	1	0.63
	<b>Weighted Average</b>			<b>3.09</b>
	<b>Total</b>			<b>6</b>
	<b>Period ended September 30, 2025*</b>			<b>18.53</b>
				3.07

\*Not Annualized

Notes:

1. The figures disclosed above are based on the Restated Financial Statements of the Company.

2. The face value of each Equity Share is ₹10.00.

3. Weighted average = Aggregate of year-wise weighted EPS divided by the aggregate of weights i.e. sum of (EPS x Weight) for each year/Total of weights.

4. Earnings per Share has been calculated in accordance with Indian Accounting Standard 33 – "Earnings per Share".

**2. Price to Earnings (P/E) ratio in relation to Price Band of ₹67 and ₹70 per Equity Shares**

Particulars	EPS (in ₹)	P/E Ratio at the Floor Price (No. of times)	P/E Ratio at the Cap Price (No. of times)
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2024-25	4.32	15.51	16.20
P/E ratio based on the Weighted Average EPS, as restated	3.09	21.68	22.65

## BID / ISSUE PROGRAMME

**ANCHOR INVESTOR BIDDING DATE OPENED AND CLOSED ON: WEDNESDAY, JANUARY 21, 2026**

**BID / ISSUE OPENED ON: THURSDAY, JANUARY 22, 2026 | BID / ISSUE CLOSED ON WEDNESDAY, JANUARY 28, 2026**

**PROPOSED LISTING: MONDAY, FEBRUARY 02, 2026\***

\*Subject to the receipt of listing and trading approval from the BSE.

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), out of which 33.33% of the Anchor Investor Portion shall be reserved for domestic Mutual Funds and 6.67% for life insurance companies and pension funds, subject to valid Bids being received from domestic Mutual Funds, life insurance companies and pension funds at or above the Anchor Investor Allocation Price, in accordance with the SEBI ICDR Regulations. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bid being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders of which (a) one-third of portion shall be reserved for applicants with application size of more than two lots and up to ₹10,00,000; and (b) two-third of such portion shall be reserved for applicants with application size of more than ₹10,00,000, provided that the unsubscribed portion in either of such sub-categories may be allocated to applicants in the other sub-category of Non-Institutional Bidders, in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price and not less than 35% of the Net Issue shall be available for allocation to Individual Bidders who applies for minimum application size in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective bank accounts (including UPI ID for UPI Bidder using the UPI Mechanism) (defined hereinafter), in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks ("SCSBs") or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page no. 256 of the Prospectus.

## SUBSCRIPTION DETAILS

The bidding for Anchor Investors opened and closed on January 21, 2026. The Company received 7 Anchor Investors applications for 2290500 Equity Shares against 1706000 Equity Shares reserved for Anchor Investors. The Anchor Investor Allocation price was finalized at ₹70 per Equity Share. A total of 1706000 Equity Shares were allotted under the Anchor Investor portion aggregating to ₹11942000/-.

The Issue (Including Anchor Investors Portion) received 887 Applications for 8666500 Equity Shares (prior to rejections) resulting in 1.35 times subscription (including reserved portion of market maker). The details of the Applications received in the Issue from various categories are as under:

**Detail of the Applications Received from various categories including market maker are as under:**

Sr. No.	Category	No. of Applications received	No. of Equity Shares applied	No. of Equity Shares reserved as per Prospectus	No. of times Subscribed	Amount (₹)
1	Qualified Institutional Bidders (excluding Anchor Investors)	5	1230000	1140000	1.08	8610000
2	Non-Institutional Investors - More than 2 Lakhs Upto 10 Lakhs	53	370000	286000	1.29	2590000
3	Non-Institutional Investors - Above 10 Lakhs	35	1332000	572000	2.33	9324000
4	Individual Investors	786	3144000	1996000	1.58	22008000
5	Anchor Investors	7	2290500	1706000	1.34	16035000
6	Market Maker	1	300000	300000	1.00	2100000
<b>Total</b>		<b>887</b>	<b>8666500</b>	<b>6000000</b>	<b>1.35</b>	<b>606655000</b>

**Final Demand:**

**A summary of final demand (prior to any rejections) as per BSE as on the Bid/Issue Closing Date at different prices is as under:**

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Share Total	Cumulative % of Total
1	67.00	296000	1.63	296000	1.63
2	68.00	142000	0.78	438000	2.41
3	69.00	56000	0.31	494000	2.72
4	70.00	1766000	97.28	18154000	100.00
<b>Total</b>		<b>18154000</b>			

The basis of allotment was finalized in consultation with the Designated Stock Exchange, being BSE Limited (BSE SME) on January 29, 2026.

**a) Allotment to Individual Investors (After Rejections & Withdrawal):**

The Basis of Allotment to the Individual Investors, who have Bid at cut-off Price or at or above the Issue Price of ₹70/- per Equity Share, was finalized in consultation with BSE SME. The category was subscribed by 1.58 times i.e., for 3144000 Equity Shares. The total number of Equity Shares allotted in this category is 1996000 Equity Shares to 499 successful applicants.

**The category wise details of the Basis of Allotment are as under:**

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each	% to total	Allocation per Applicant	Ratio of allottees to applicants	Number of successful applicants (after rounding)	% to total	Total No. of shares allocated/ allotted	% to total	Surplus/ Deficit (14)-(7)
				Before Rounding (8)		After Rounding (9)						